Two Real Patients Lost Over 100 Pounds Combined on GLP-1s — Here's the Full Story

When the Food Noise Finally Goes Quiet

A story about a 75-year-old woman in London and a registered nurse in America doesn't sound like the kind of thing that would break the internet. But that's exactly what happened when Healthline's Editor-in-Chief Robin Hough turned the lens on the people closest to him to explore one of the most talked-about drug classes in modern medicine: GLP-1 medications.

Hough spoke with his mother, Catherine, who lost 56 pounds on tirzepatide, and a registered nurse who has lost over 50 pounds, discussing the benefits, side effects, and cost of long-term treatment. Together, their stories represent what millions of Americans are quietly living through — a treatment that can feel miraculous and miserable, sometimes in the same week.

A Healthline story on actress Mayim Bialik's GLP-1 side effects became the outlet's most engaged Facebook post of the year, as thousands of commenters shared both hard side effects and life-changing results. That wave of public response made clear that this isn't just a medical conversation — it's a deeply personal one.

Catherine's Story: 56 Pounds and a Quieter Mind

Catherine was a hockey player and distance runner in her youth — the kind of person who could eat what she liked without it showing. Then came children, and a weight that crept up year after year, with decades of diets that "worked for a couple of months only to be back to my former weight and then some." In late 2024, after extensive research, she decided to try tirzepatide.

She has since lost 56 pounds and reports reduced joint pain and a significant decrease in the intrusive thoughts about food often described as "food noise." Catherine is firm in her belief that obesity is a disease and not the result of overindulgence or laziness, and that GLP-1s have greatly improved her health and self-esteem after years of struggling. But the journey wasn't without a price. She'll also tell you what it cost her: nausea, constipation, and sulfur-tasting burps with rough nights of indigestion.

Many patient accounts expand on the difficult side effect battles, but plenty also tell the other side of the story: years of failed diets and struggles with chronic conditions leading to despondency, side effects that eased with time, and life-changing results that were ultimately worth the cost. Catherine's experience lands squarely in that second camp.

What the Science — and Surveys — Actually Show

Gastrointestinal side effects are often a major concern when considering GLP-1 medications, but Healthline's own 2026 survey suggests that what people expect to experience may not always match what those actually taking a GLP-1 report. In a 2025 survey of 1,262 people, 52% experienced nausea and 34% experienced diarrhea — numbers that sound alarming until you consider that many of those symptoms ease as the body adjusts to the medication.

Facial volume loss — often called "Ozempic face" — has become one of the more widely discussed GLP-1-related concerns, but expectations may far exceed reality. Among those planning to take a GLP-1, 44% expected dramatic facial changes, while only 20% of those who had actually taken one reported experiencing this side effect. Beyond weight loss, other reported benefits include lower blood pressure and cholesterol, improved cardiac function, and a lower risk of cardiac events — substantial advantages affecting key factors in diabetes, renal disease, heart disease, and stroke.

The Cost Question Nobody Wants to Answer

The sticker price of a brand-name GLP-1 runs roughly $1,000 to $1,350 per month at list price, but what patients actually pay depends on whether their insurance covers the drug for weight loss, whether they qualify for a manufacturer savings card, and whether they buy through a manufacturer's cash-pay program. GLP-1 insurance coverage for weight loss is not guaranteed and varies significantly by plan type, while Medicare's 2026 Bridge program offers temporary access for $50 per month.

Among people who had taken a GLP-1 for less than three months, 8% reported no benefits — compared with 92% who reported at least one. Among those who had been on a GLP-1 for more than three years, zero percent reported no benefits at all. That trajectory suggests the longer patients stay the course — navigating the nausea, the cost, and the uncertainty — the more likely they are to find the results worth it. For Catherine, and for the nurse Hough interviewed, that calculation has already been made.